Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176951 | 1.00 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7CHRM2CHRM5 | |
| SCHEMBL7012875 | 0.94 | MEN1 (0.49) | CHRNB2CHRNA4CHRNA7CHRM2CHRM5 | |
| SCHEMBL9362322 | 0.93 | MEN1 (0.47) | CHRNB2CHRNA4CHRNA7CHRM2CHRM5 | |
| SCHEMBL3014722 | 0.76 | PARP1 (0.31) | POLBSMN1; SMN2 | |
| SCHEMBL3871908 | 0.76 | CYP19A1 (0.33) | POLBSMN1; SMN2 | |
| SCHEMBL27320198 | 0.72 | DRD2 (0.45) | CYP2D6 | |
| SCHEMBL7513415 | 0.72 | ADORA2B (0.33) | — | |
| SCHEMBL167264 | 0.71 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA7CHRM2CHRM5 | |
| SCHEMBL21232 | 0.71 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA7CHRM2CHRM5 | |
| SCHEMBL170704 | 0.71 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA7CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504448-A | Synthesis method of 3',4',5' -trifluoro-2-aminobiphenyl | 河北八亿时空药业有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119504448-A | Synthesis method of 3',4',5' -trifluoro-2-aminobiphenyl | 河北八亿时空药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-11161863-B2 | Chiral catalyst and method for asymmetric reduction of an imine | DALHOUSIE UNIVERSITY (CA) | 2021-11-02 | — | — | US | disclosed |
| US-20200255463-A1 | CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE | DALHOUSIE UNIVERSITY (CA) | 2020-08-13 | — | — | US | disclosed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255463-A1 | CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE | C1R, C5, C1S | CHRNB2 2141/4885CHRNA4 2235/4885CHRNA7 1917/4885 |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MTHFD1, TYMS, DPYD | CHRNB2 4639/4885CHRNA4 4688/4885CHRNA7 4691/4885 |
| US-11161863-B2 | Chiral catalyst and method for asymmetric reduction of an imine | C1R, C5, C1S | CHRNB2 2141/4885CHRNA4 2235/4885CHRNA7 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.